Skip to content

艾万拓

US · AVTR #1438 按市值排名 上市于 2019
16.42 +0.33 +2.05%
实时 - 追踪5344个代码 - 心跳于400秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 1.92 低于历史水平 第32百分位
5年平均 3.13 · 在Medical Instruments & Supplies中排名第17/51
市盈率 -18.76 低于历史水平 第6百分位
5年平均 21.60 · 前瞻 38.71
市销率 1.64 低于历史水平 第31百分位
5年平均 1.96 · 前瞻 1.62 · 在Medical Instruments & Supplies中排名第13/51

同业对比 Medical Instruments & Supplies

公司 市值 市盈率(TTM) 市净率 股息率
艾万拓 (AVTR) 11.11B -19.32 1.97 0.00%
Intuitive Surgical (ISRG) 150.74B 48.93 8.30 0.00%
Becton Dickinson & Co (BDX) 52.23B 57.93 2.14 2.19%
ResMed (RMD) 33.61B 22.91 5.10 1.00%
Alcon (ALC) 31.99B 50.52 1.48 0.53%
Medline (MDLN) 31.55B 68.24 2.73 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★★ 合理价值19.31 经济护城河None 不确定性High

当前股价低于晨星合理价值估算17.6%。

合理价值

Avantor Inc is assigned a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 18% discount to our quantitative fair value estimate of $19.31 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 1.3 sits in the top 30% compared with peers globally. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. We believe this is a sign that shares could be cheap.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -2.9%, a core component of profitability, lies in the bottom 20% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

艾万拓 讨论区 0 条评论

发表评论